NCP system

NCP system

Abbreviation for:
NeuroCybernetic Prosthesis system (see there)
References in periodicals archive ?
Up to 30 patients at four study sites will be implanted with the NCP System and treated with left cervical (neck area) vagus nerve stimulation similar to the VNS being used to treat patients with epilepsy, depression and Alzheimer's Disease.
VNS with the Cyberonics NCP System received European CE Mark approval in March 2001 for the treatment of patients with treatment-resistant or treatment-intolerant, chronic or recurrent depression, including major depression (unipolar) and bipolar disorder (manic depression).
VNS therapy is delivered by the Cyberonics NCP System, an implantable medical device similar to a cardiac pacemaker, which delivers mild electrical stimulation to the left vagus nerve in the patient's neck.
His Cyberonics responsibilities will include epilepsy marketing, global launches of new NCP System products and new indications launches and marketing, including Vagus Nerve Stimulation (VNS) as a treatment for chronic or recurrent depression.
The NCP System and VNS therapy are covered by a variety of method and device patents.
The NCP System consists of a pacemaker-like electrical pulse generator and a nerve stimulation electrode that delivers intermittent electrical stimulation to the left vagus nerve in the patient's neck.
VNS with the Cyberonics NCP System was approved by the FDA on July 16, 1997 for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with medically refractory partial onset seizures.
Vagus nerve stimulation with the Cyberonics NCP System was approved by the FDA on July 16, 1997 for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with medically refractory partial onset seizures.
In addition, the NCP System is currently approved for epilepsy in all the member countries of the European Union, Canada, Australia and other markets.
Cyberonics is conducting investigational studies with the NCP System and its effects on chronic treatment-resistant depression, and plans to initiate a clinical investigation into the treatment of morbid obesity - both of which represent major health problems.
the NCP System is currently approved for sale as a treatment for epilepsy in all the member countries of the European Union, Canada and other markets.
NASDAQ/NMS:CYBX) today announced that study results presented by physicians from New York Presbyterian Hospital at the 1999 American Academy of Neurology Annual Conference indicate that Vagus Nerve Stimulation (VNS) with the Cyberonics NCP System may have an effect on improving mood in epilepsy patients, which is independent of its effect on reducing seizure frequency.